{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/bntx-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/bntx-stock-analysis/data.json",
 "title": "BioNTech SE (BNTX) Stock Forecast & Price Target (2026)",
 "description": "BioNTech SE (BNTX) stock: Healthcare, Biotechnology. $24.3B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "BioNTech SE (BNTX)",
 "published": "2026-07-16T09:55:46+00:00",
 "modified": "2026-09-16T07:20:55.005+00:00",
 "generated": "2026-09-16T11:57:59.575Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "BNTX",
  "name": "BioNTech SE",
  "type": "American Depositary Receipt",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "Germany",
  "website": "https://www.biontech.de"
 },
 "quote": {
  "price": 96.69,
  "previousClose": 98.86,
  "change": -2.17,
  "changePercent": -2.2,
  "open": 97.040001,
  "high": 97.66,
  "low": 95.8,
  "volume": 590400,
  "averageVolume": 918810,
  "marketCap": 24288950148,
  "fiftyTwoWeekHigh": 124,
  "fiftyTwoWeekLow": 79.52,
  "marketOpen": false,
  "asOf": "2026-09-16T07:20:54.000Z"
 },
 "statistics": {
  "pe": -12.43,
  "eps": -7.78,
  "dividendYield": 0,
  "beta": 1.293,
  "priceToSales": 9.3713455,
  "priceToBook": 1.205517,
  "revenueTtm": 3059451352,
  "grossMargin": 0.08143939393939394,
  "returnOnEquity": -0.09300999
 },
 "technicals": {
  "rsi": 19.48,
  "macd": -0.12,
  "sma50": 96.94,
  "sma200": 97.63,
  "rsiSignal": "Oversold",
  "trend": "Neutral",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 66,
  "consensus": "Buy",
  "fairValue": 96.69,
  "analystTarget": 126.35,
  "analystCount": 20,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-16T07:20:54.000Z",
  "priceAtAnalysis": 96.69,
  "volatility": {
   "daily": 4.74,
   "risk": "volatile"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 94.76,
  "aggressiveEntry": 96.69,
  "stopLoss": 87.34,
  "stopLossPercent": 7.83,
  "targets": [
   99.49,
   104.23,
   108.97
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 59.17,
    "base": 112.3,
    "upside90th": 213.14
   },
   {
    "year": 2028,
    "downside10th": 52.7,
    "base": 130.42,
    "upside90th": 322.79
   },
   {
    "year": 2029,
    "downside10th": 49.92,
    "base": 151.47,
    "upside90th": 459.58
   },
   {
    "year": 2030,
    "downside10th": 48.83,
    "base": 175.92,
    "upside90th": 633.74
   },
   {
    "year": 2031,
    "downside10th": 48.75,
    "base": 204.32,
    "upside90th": 856.24
   },
   {
    "year": 2032,
    "downside10th": 49.39,
    "base": 237.3,
    "upside90th": 1140.19
   },
   {
    "year": 2033,
    "downside10th": 50.58,
    "base": 275.6,
    "upside90th": 1501.69
   },
   {
    "year": 2034,
    "downside10th": 52.25,
    "base": 320.08,
    "upside90th": 1960.66
   },
   {
    "year": 2035,
    "downside10th": 54.37,
    "base": 371.75,
    "upside90th": 2541.77
   },
   {
    "year": 2036,
    "downside10th": 56.91,
    "base": 431.75,
    "upside90th": 3275.53
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "BNTX Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$97.04",
    "Day Range": "$95.80 to $97.66",
    "Prev Close": "$98.86",
    "Volume": "590.4K",
    "52-Week Range": "$79.52 to $124.00",
    "Market Cap": "$24.29B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a significant premium to sector peers (+404%), suggesting market expectations for superior growth or market position."
   ]
  },
  {
   "id": "financials",
   "title": "BNTX Financial Performance",
   "text": [
    "Analysis: In the last 3 quarters, BNTX beat estimates 1 times. However, the stock fell 1 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "BNTX Analysis",
   "text": [
    "BioNTech SE (BNTX) is exhibiting bearish momentum with its Relative Strength Index (RSI) at 19.48, indicating an oversold condition that could signal a potential reversal, though it also reflects strong selling pressure. The stock is trading below its 20-day, 50-day, and 200-day moving averages, with the 50-day SMA at $96.94 and the 200-day SMA at $97.63, reinforcing the current downtrend. The Moving Average Convergence Divergence (MACD) is at -0.117, also suggesting bearish momentum. Key support levels are being tested as the stock trades below its critical moving averages. Volume has been below average recently, with the latest volume at 590,400 compared to an average of 918,810, suggesting a lack of conviction from buyers. The current price action indicates that the stock is in a significant downtrend, and a sustained move above the 50-day SMA would be required to signal a potential shift in momentum.",
    "BioNTech SE (BNTX) reported an EPS beat of $2.62 vs. an estimate of $2.51 for the quarter ending June 2026, indicating operational performance exceeding analyst expectations for that period.",
    "Insiders have sold a total of $20.6 million in BioNTech SE (BNTX) stock across three transactions, with no reported purchases, signaling a moderate sell signal and potentially reduced insider confidence.",
    "BioNTech SE (BNTX) reported a -59.5% revenue growth and faces projections for further revenue contraction, with current quarter estimates showing a -30.00% year-over-year decrease.",
    "Despite current challenges, 13 out of 20 analysts rate BioNTech SE (BNTX) as Buy or Strong Buy, with a median price target of $126.35, suggesting a 30.7% upside from the current price.",
    "BioNTech SE (BNTX) faces a challenging outlook, with current revenue trends and analyst estimates pointing towards continued contraction in the near to medium term. The company's next year revenue is projected to be $1.8 billion, with a slight growth of +0.00% year-over-year, and a concerning -64.5% compound annual growth rate projected over the next five years. The stock's current price of $96.69 is below key moving averages, and the oversold RSI suggests potential for a short-term bounce, but a sustained recovery will likely depend on new product catalysts or significant shifts in its clinical pipeline. Upside potential hinges on successful development and commercialization of new therapies beyond its COVID-19 vaccine, which has seen declining sales. Downside risks include continued revenue erosion, failure to gain regulatory approval for new drug candidates, and increased competition in the biotechnology sector. The moderate insider selling also adds a layer of caution, suggesting management's near-term confidence may be limited."
   ],
   "lists": {
    "ProTips": [
     "BioNTech SE (BNTX) is trading at an oversold RSI of 19.48, suggesting a potential short-term bounce, but the stock remains below its 50-day and 200-day moving averages ($96.94 and $97.63), indicating a bearish trend. Consider waiting for a confirmed break above resistance levels before initiating new positions.",
     "With a significant revenue decline of -59.5% and projected further contractions, investors should closely monitor BioNTech SE's (BNTX) pipeline developments and upcoming clinical trial results for potential catalysts.",
     "Given the moderate insider selling and negative profitability, BioNTech SE (BNTX) presents a higher risk profile. A stop-loss order below the current oversold technical levels may be prudent for risk management."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Positive Earnings Surprise in June 2026 Quarter",
     "text": "BioNTech SE (BNTX) reported an EPS beat of $2.62 vs. an estimate of $2.51 for the quarter ending June 2026, indicating operational performance exceeding analyst expectations for that period.",
     "source": "Company Earnings Report"
    },
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling Activity",
     "text": "Insiders have sold a total of $20.6 million in BioNTech SE (BNTX) stock across three transactions, with no reported purchases, signaling a moderate sell signal and potentially reduced insider confidence.",
     "source": "Insider Transaction Filings"
    },
    {
     "type": "Bearish",
     "title": "Continued Revenue Decline and Negative Growth Projections",
     "text": "BioNTech SE (BNTX) reported a -59.5% revenue growth and faces projections for further revenue contraction, with current quarter estimates showing a -30.00% year-over-year decrease.",
     "source": "Analyst Estimates"
    },
    {
     "type": "Bullish",
     "title": "Strong Wall Street Buy Consensus and Upside Potential",
     "text": "Despite current challenges, 13 out of 20 analysts rate BioNTech SE (BNTX) as Buy or Strong Buy, with a median price target of $126.35, suggesting a 30.7% upside from the current price.",
     "source": "Wall Street Analysts"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "BioNTech SE (BNTX) presents a challenging fundamental picture, with a negative EPS of -7.78 and a net profit margin of -63.64%, indicating significant losses. The company's price-to-sales ratio stands at 9.37, which is considerably higher than the sector median of 3.7, suggesting a premium valuation relative to its sales, especially given its negative profitability. Its return on equity is -9.30%, further underscoring its current financial struggles. While the company maintains a very low debt-to-equity ratio of 0.02, providing some balance sheet stability, the steep revenue decline of -59.5% and projected further contractions in the coming quarters are major concerns. The current valuation appears stretched given the negative earnings and declining revenue trajectory, contrasting sharply with the sector's average revenue growth of 8.1%. Investors should carefully consider the high price-to-sales ratio in light of the company's current profitability and growth challenges.",
    "BioNTech SE (BNTX) most recently reported an EPS beat for the quarter ending June 2026, with actual EPS of $2.62 exceeding the estimate of $2.51 by 4.38%, though the stock price declined 2.44% on the news. This followed a miss in the prior quarter ending March 2026, where EPS was -1.95 against an estimate of -1.92, a surprise of -1.56%. Prior to that, the quarter ending March 2026 also saw an EPS miss of -0.33 versus an estimate of -0.25. The company's revenue is projected to decline significantly, with current quarter revenue estimates showing a -30.00% year-over-year decrease.",
    "BioNTech SE (BNTX) faces significant risks including a sharp decline in revenue, down 59.5%, with further contractions projected in the coming quarters. The company is currently loss-making, with a negative EPS of -7.78 and a net profit margin of -63.64%, raising concerns about its long-term financial sustainability. Also, insider activity shows a moderate sell signal, with $20.6 million in sales and no reported purchases, indicating a lack of insider confidence in the near-term outlook."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "24.29B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-7.78"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "124.00"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "79.52"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Oversold SMA Cross Neutral Price vs SMA Bearish MACD Bearish Price is trading below the 50-day SMA, RSI at 19.5 suggests oversold conditions; potential bounce setup."
   ],
   "facts": {
    "RSI": "Oversold",
    "SMA Cross": "Neutral",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "19.48"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-0.12"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "96.94"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "97.63"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.30",
    "Correlation with Nasdaq 100 (QQQ)": "+0.25",
    "Correlation with Bitcoin (BTC)": "+0.24",
    "Correlation with Gold (XAU)": "+0.18"
   }
  },
  {
   "id": "trade-plans",
   "title": "BNTX Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (19.5) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$99.49",
    "TARGET 2": "$104.23",
    "TARGET 3": "$108.97",
    "STOP LOSS": "$87.34"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "-1.06%",
    "Average Feb return": "-3.66%",
    "Average Mar return": "+5.48%",
    "Average Apr return": "+6.76%",
    "Average May return": "+2.41%",
    "Average Jun return": "+0.85%",
    "Average Jul return": "+12.32%",
    "Average Aug return": "-0.73%",
    "Average Sep return": "+2.55%",
    "Average Oct return": "+3.51%",
    "Average Nov return": "+18.96%",
    "Average Dec return": "-0.96%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "4.74%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in BNTX in October 2019 would be worth about $67,900 today, compared with about $25,828 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BNTX today could grow to about $44,653 by 2036 in the base case, with a bull case near $338,766 and a bear case around $5,886. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "BNTX Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $176 for BNTX by 2030 in the base case, from $96.69 today (1.8x over 4 years). The downside path ends near $48.83. These are outcomes of a Monte Carlo simulation run on BNTX's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using BNTX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. BNTX is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "BNTX simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$59.17",
        "$112",
        "$213"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$52.70",
        "$130",
        "$323"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$49.92",
        "$151",
        "$460"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$48.83",
        "$176",
        "$634"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$48.75",
        "$204",
        "$856"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$49.39",
        "$237",
        "$1,140"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$50.58",
        "$276",
        "$1,502"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$52.25",
        "$320",
        "$1,961"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$54.37",
        "$372",
        "$2,542"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$56.91",
        "$432",
        "$3,276"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "ZTS Zoetis Inc. NYSE $73.43 -0.33%",
     "url": "https://clearank.com/stock/zts-stock-analysis/"
    },
    {
     "text": "GEHC GE HealthCare Technologies Inc. NASDAQ $64.07 -0.28%",
     "url": "https://clearank.com/stock/ge-healthcare-gehc/"
    },
    {
     "text": "IONS Ionis Pharmaceuticals, Inc. NASDAQ $47.25 -8.15%",
     "url": "https://clearank.com/stock/ions-stock-analysis/"
    },
    {
     "text": "WST West Pharmaceutical Services Inc. NYSE $355.20 +2.59%",
     "url": "https://clearank.com/stock/wst-stock-analysis/"
    },
    {
     "text": "RMD ResMed Inc. NYSE $229.44 +2.89%",
     "url": "https://clearank.com/stock/rmd-stock-analysis/"
    },
    {
     "text": "TEM Tempus AI Inc NASDAQ $68.85 +10.67%",
     "url": "https://clearank.com/stock/tempus-ai-tem/"
    },
    {
     "text": "IQV IQVIA Holdings Inc. NYSE $269.67 +1.51%",
     "url": "https://clearank.com/stock/iqvia-iqv/"
    },
    {
     "text": "IDXX IDEXX Laboratories, Inc. NASDAQ $510.73 +0.23%",
     "url": "https://clearank.com/stock/idxx-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "CLS vs SMCI Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/cls-vs-smci/"
    },
    {
     "text": "JPM vs BAC Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/jpm-vs-bac/"
    },
    {
     "text": "VUG vs VOOG Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vug-vs-voog/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "BNTX Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$20.6M",
    "Insiders": "2",
    "Avg Transaction": "$6.9M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in BNTX",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Sep 4, 2026",
       "cells": [
        "SAHIN UGUR MD Chief Executive Officer",
        "Sell",
        "76.5K",
        "$7.9M"
       ]
      },
      {
       "label": "Sep 9, 2026",
       "cells": [
        "SAHIN UGUR MD Chief Executive Officer",
        "Sell",
        "73.0K",
        "$7.2M"
       ]
      },
      {
       "label": "Apr 22, 2026",
       "cells": [
        "POETTING SIERK Chief Operating Officer",
        "Sell",
        "50.0K",
        "$5.5M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=BioNTech+SE&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is BioNTech SE's (BNTX) current stock price and consensus rating?",
   "answer": "BioNTech SE (BNTX) is currently trading at $96.69. The consensus rating among 20 Wall Street analysts is predominantly 'Buy', with a score of 66 out of 100."
  },
  {
   "question": "What is the median analyst price target for BNTX stock?",
   "answer": "The median analyst price target for BioNTech SE (BNTX) is $126.35, which represents an upside potential of approximately 30.7% from its current trading price of $96.69."
  },
  {
   "question": "How has BioNTech SE's revenue performed recently?",
   "answer": "BioNTech SE (BNTX) has experienced a significant revenue decline of -59.5%. Current quarter revenue estimates project a further year-over-year decrease of -30.00%, indicating continued revenue contraction."
  },
  {
   "question": "What are the key technical indicators for BNTX stock?",
   "answer": "BNTX's technical indicators show bearish momentum, with an RSI at 19.5 (oversold) and the stock trading below its 50-day and 200-day moving averages ($96.94 and $97.63). Volume has also been below average."
  },
  {
   "question": "What is BioNTech SE's profitability and valuation status?",
   "answer": "BioNTech SE (BNTX) is currently loss-making with a negative EPS of -7.78 and a net profit margin of -63.64%. Its price-to-sales ratio of 9.37 is high compared to the sector median of 3.7."
  },
  {
   "question": "Are insiders buying or selling BioNTech SE (BNTX) stock?",
   "answer": "Insiders are net sellers of BioNTech SE (BNTX) stock. There have been no reported insider purchases, while total insider sales amount to $20.6 million across three transactions, signaling a moderate sell signal."
  },
  {
   "question": "What is BioNTech SE's (BNTX) stock forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, BioNTech SE's (BNTX) stock forecast for 2030 includes a base case price of $175.92 and a downside case of $48.83. These are statistical outcomes, not guarantees."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "ZTS",
    "name": "Zoetis Inc. NYSE",
    "price": "$73.43",
    "change": "-0.33%",
    "url": "https://clearank.com/stock/zts-stock-analysis/"
   },
   {
    "ticker": "GEHC",
    "name": "GE HealthCare Technologies Inc. NASDAQ",
    "price": "$64.07",
    "change": "-0.28%",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "IONS",
    "name": "Ionis Pharmaceuticals, Inc. NASDAQ",
    "price": "$47.25",
    "change": "-8.15%",
    "url": "https://clearank.com/stock/ions-stock-analysis/"
   },
   {
    "ticker": "WST",
    "name": "West Pharmaceutical Services Inc. NYSE",
    "price": "$355.20",
    "change": "+2.59%",
    "url": "https://clearank.com/stock/wst-stock-analysis/"
   },
   {
    "ticker": "RMD",
    "name": "ResMed Inc. NYSE",
    "price": "$229.44",
    "change": "+2.89%",
    "url": "https://clearank.com/stock/rmd-stock-analysis/"
   },
   {
    "ticker": "TEM",
    "name": "Tempus AI Inc NASDAQ",
    "price": "$68.85",
    "change": "+10.67%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   },
   {
    "ticker": "IQV",
    "name": "IQVIA Holdings Inc. NYSE",
    "price": "$269.67",
    "change": "+1.51%",
    "url": "https://clearank.com/stock/iqvia-iqv/"
   },
   {
    "ticker": "IDXX",
    "name": "IDEXX Laboratories, Inc. NASDAQ",
    "price": "$510.73",
    "change": "+0.23%",
    "url": "https://clearank.com/stock/idxx-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "CLS vs SMCI Comparison",
    "name": "",
    "url": "https://clearank.com/compare/cls-vs-smci/"
   },
   {
    "ticker": "JPM vs BAC Comparison",
    "name": "",
    "url": "https://clearank.com/compare/jpm-vs-bac/"
   },
   {
    "ticker": "VUG vs VOOG Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vug-vs-voog/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "GWRE",
    "text": "Guidewire Software Inc.",
    "url": "https://clearank.com/stock/gwre-stock-analysis/"
   },
   {
    "ticker": "ROST",
    "text": "Ross Stores Inc.",
    "url": "https://clearank.com/stock/rost-stock-analysis/"
   },
   {
    "ticker": "LUGDF",
    "text": "Lundin Gold Inc",
    "url": "https://clearank.com/stock/lugdf-stock-analysis/"
   },
   {
    "ticker": "KEYS",
    "text": "Keysight Technologies, Inc.",
    "url": "https://clearank.com/stock/keys-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "CRCL",
    "text": "↓ 11.41%",
    "url": "https://clearank.com/stock/circle-internet-group-crcl/"
   },
   {
    "ticker": "TEM",
    "text": "↑ 10.67%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   },
   {
    "ticker": "COIN",
    "text": "↓ 10.10%",
    "url": "https://clearank.com/stock/coinbase-coin/"
   },
   {
    "ticker": "AXON",
    "text": "↓ 9.98%",
    "url": "https://clearank.com/stock/axon-enterprise-axon/"
   },
   {
    "ticker": "AERO/USD",
    "text": "↓ 9.65%",
    "url": "https://clearank.com/crypto/aero-usd-crypto-analysis/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "CAPR",
    "text": "Capricor Therapeutics, Inc.",
    "url": "https://clearank.com/stock/capr-stock-analysis/"
   },
   {
    "ticker": "CRNX",
    "text": "Crinetics Pharmaceuticals",
    "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
   },
   {
    "ticker": "CRSP",
    "text": "CRISPR Therapeutics AG",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   },
   {
    "ticker": "FBRX",
    "text": "Forte",
    "url": "https://clearank.com/stock/fbrx-stock-analysis/"
   },
   {
    "ticker": "IONS",
    "text": "Ionis",
    "url": "https://clearank.com/stock/ions-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/BNTX-biontech-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/BNTX-biontech-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "BioNTech (BNTX) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/bntx-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/bntx-stock-analysis/",
        "name": "BioNTech SE (BNTX) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/bntx-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/bntx-stock-analysis/",
     "name": "BioNTech SE (BNTX) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-16T09:55:46+00:00",
     "dateModified": "2026-09-16T07:20:55+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/BNTX-biontech-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/bntx-stock-analysis/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/bntx-stock-analysis/#richSnippet",
     "headline": "BioNTech SE (BNTX) Stock Forecast & Price Target (2026)",
     "name": "BioNTech SE (BNTX) Stock Forecast & Price Target (2026)",
     "description": "BioNTech SE (BNTX) stock: Healthcare, Biotechnology. $24.3B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-16T09:55:46+00:00",
     "dateModified": "2026-09-16T07:20:55+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "BioNTech SE",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "BNTX"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NASDAQ"
       }
      ],
      "description": "BioNTech SE American Depositary Share is the U.S.-traded depositary share of BioNTech SE, a Germany-based biotechnology company focused on immunotherapy and vaccines. The company develops cancer therapeutics, including individualized treatment approaches such as personalized immunotherapies, and als",
      "tickerSymbol": "BNTX",
      "sameAs": "https://www.biontech.de"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/bntx-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/BNTX-biontech-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/bntx-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is BioNTech SE's (BNTX) current stock price and consensus rating?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "BioNTech SE (BNTX) is currently trading at $96.69. The consensus rating among 20 Wall Street analysts is predominantly 'Buy', with a score of 66 out of 100."
     }
    },
    {
     "@type": "Question",
     "name": "What is the median analyst price target for BNTX stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The median analyst price target for BioNTech SE (BNTX) is $126.35, which represents an upside potential of approximately 30.7% from its current trading price of $96.69."
     }
    },
    {
     "@type": "Question",
     "name": "How has BioNTech SE's revenue performed recently?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "BioNTech SE (BNTX) has experienced a significant revenue decline of -59.5%. Current quarter revenue estimates project a further year-over-year decrease of -30.00%, indicating continued revenue contraction."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key technical indicators for BNTX stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "BNTX's technical indicators show bearish momentum, with an RSI of 19.48 (oversold) and the stock trading below its 50-day and 200-day moving averages. Volume has also been below average."
     }
    },
    {
     "@type": "Question",
     "name": "What is BioNTech SE's profitability and valuation status?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "BioNTech SE (BNTX) is currently loss-making with a negative EPS of -7.78 and a net profit margin of -63.64%. Its price-to-sales ratio of 9.37 is high compared to the sector median of 3.7."
     }
    },
    {
     "@type": "Question",
     "name": "Are insiders buying or selling BioNTech SE (BNTX) stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insiders are net sellers of BioNTech SE (BNTX) stock. There have been no reported insider purchases, while total insider sales amount to $20.6 million across three transactions, signaling a moderate sell signal."
     }
    },
    {
     "@type": "Question",
     "name": "What is BioNTech SE's (BNTX) stock forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, BioNTech SE's (BNTX) stock forecast for 2030 includes a base case price of $175.92 and a downside case of $48.83. These are statistical outcomes, not guarantees."
     }
    }
   ]
  }
 ]
}